NR3C2 and Gynecomastia: The more recent MRAs, eplerenone and finerenone, have different pharmacologic profiles (e.g., decreased prevalence of antiandrogenic side effects, including gynecomastia and hyperkalemia, and greater selectivity for mineralocorticoid receptors).